PharmEasy is poised for a stronger financial future as Manipal Group proposes a substantial investment. This injection of funds will enable the online pharmacy leader to significantly reduce its debt and enhance its market position, setting the stage for future growth and profitability.
PharmEasy, a leading name in India's online pharmacy sector, is on track to fortify its financial stability, with the Manipal Group proposing a significant investment of Rs 1,000 crore. This investment is earmarked to provide the online pharmacy major's parent company, API Holdings, with the resources to strategically repay its existing debt, signaling a positive outlook for the company's future.
This potential deal involves Manipal Group acquiring an 18% stake in API Holdings, marking a crucial step towards alleviating its debt burden, which reportedly stands at Rs 2,500 crore. A strategic move in this direction, API Holdings had previously secured its debt by pledging shares of its subsidiary, Thyrocare, to Goldman Sachs. Looking back, API Holdings demonstrated its strategic expansion by acquiring a 66% stake in Thyrocare back in June 2021 for Rs 4,546 crore.
The Manipal Group's confidence in PharmEasy is further highlighted by the potential acquisition of a board seat at API Holdings. Moreover, existing investors are also anticipated to contribute an additional Rs 1,500 crore in a funding round spearheaded by the Manipal Group. This collaborative effort is set to elevate the total valuation of API Holdings to an impressive Rs 6,000 crore.
According to reports, this financial restructuring is set to position Manipal Group as the single largest shareholder in API Holdings, demonstrating a strong commitment to the online pharmacy's long-term success. Ranjan Pai, Chairman of the Manipal Group, is anticipated to take a seat on the company's board and invest in the rights issue. Existing shareholders TPG and Temasek are expected to lead this rights issue, with new stock issued at Rs 5 per share.
PharmEasy remains focused on profitability, having already made substantial strides in reducing its monthly operational losses. The company has successfully curbed its monthly operational loss from Rs 86 crore in March 2022 to approximately Rs 5.6 crore by March 2023, a noteworthy achievement that underscores its commitment to financial discipline.
API Holdings reported consolidated net sales of Rs 5,728.8 crore in FY22, according to regulatory filings. While losses amounted to Rs 3,992.4 crore in the same period, the operational loss was significantly lower at around Rs 850 crore, demonstrating signs of improving financial health. This strategic investment and restructuring effort will provide PharmEasy with a stronger financial base, enabling it to further its mission of providing accessible and affordable healthcare services across India.
